奥沙拉嗪治疗活动期溃疡性结肠炎。
Olsalazine in active ulcerative colitis.
作者信息
Selby W S, Barr G D, Ireland A, Mason C H, Jewell D P
出版信息
Br Med J (Clin Res Ed). 1985 Nov 16;291(6506):1373-5. doi: 10.1136/bmj.291.6506.1373.
Abstract
Olsalazine (azodisalicylate) is a new drug in which two molecules of 5-aminosalicylic acid are linked by an azo bond. Its role in the treatment of mildly active, distal ulcerative colitis was investigated. Sixty patients were randomly allocated to receive olsalazine 1 g or a placebo as a retention enema nightly for two weeks. Clinical improvement was seen in 19 (66%) and sigmoidoscopic improvement in 17 (59%) of the 29 patients receiving olsalazine compared with 12 (43%) and 11 (39%), respectively, of the 28 in the control group. These differences were not significant. In a second trial 40 patients were randomised to receive oral olsalazine 2 g daily or a placebo capsule for two weeks. Significant clinical and sigmoidoscopic improvement was seen in the patients receiving oral olsalazine compared with the patients receiving placebo capsules. Oral olsalazine may be valuable in the treatment of mildly active ulcerative colitis. Its role in maintaining remission is yet to be determined.
摘要
奥沙拉嗪（偶氮二水杨酸）是一种新药，其中两分子的5-氨基水杨酸通过一个偶氮键相连。对其在治疗轻度活动性远端溃疡性结肠炎中的作用进行了研究。60名患者被随机分配，每晚接受1克奥沙拉嗪或安慰剂保留灌肠，为期两周。接受奥沙拉嗪治疗的29名患者中，19名（66%）有临床改善，17名（59%）有乙状结肠镜检查改善，而对照组的28名患者中分别为12名（43%）和11名（39%）。这些差异不显著。在第二项试验中，40名患者被随机分配，每天口服2克奥沙拉嗪或服用安慰剂胶囊，为期两周。与接受安慰剂胶囊的患者相比，接受口服奥沙拉嗪的患者有显著的临床和乙状结肠镜检查改善。口服奥沙拉嗪在治疗轻度活动性溃疡性结肠炎中可能有价值。其在维持缓解中的作用尚待确定。
相似文献
1
Olsalazine in active ulcerative colitis.奥沙拉嗪治疗活动期溃疡性结肠炎。
Br Med J (Clin Res Ed). 1985 Nov 16;291(6506):1373-5. doi: 10.1136/bmj.291.6506.1373.
2
Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.奥沙拉秦钠治疗对柳氮磺胺吡啶不耐受的溃疡性结肠炎患者。一项前瞻性、随机、安慰剂对照、双盲、剂量范围临床试验。
Gastroenterology. 1987 Dec;93(6):1255-62. doi: 10.1016/0016-5085(87)90253-8.
3
Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition.
Scand J Gastroenterol Suppl. 1988;148:61-9. doi: 10.3109/00365528809101552.
4
Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.
Scand J Gastroenterol Suppl. 1988;148:29-37. doi: 10.3109/00365528809101544.
5
Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.美沙拉嗪和奥沙拉嗪：用于治疗炎症性肠病的5-氨基水杨酸制剂。
Clin Pharm. 1992 Jun;11(6):514-28.
6
Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial.用4-氨基水杨酸灌肠剂治疗左侧溃疡性结肠炎。一项双盲、安慰剂对照试验。
Ann Intern Med. 1988 Feb;108(2):195-9. doi: 10.7326/0003-4819-108-2-195.
7
Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial.奥沙拉嗪与安慰剂治疗轻至中度溃疡性结肠炎的随机双盲试验
Gut. 1989 Oct;30(10):1354-61. doi: 10.1136/gut.30.10.1354.
8
5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial.5-氨基水杨酸灌肠剂治疗难治性远端溃疡性结肠炎：一项随机对照试验。
Am J Gastroenterol. 1986 Jun;81(6):412-8.
9
A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.口服环丙沙星治疗急性溃疡性结肠炎的前瞻性随机对照试验。
Am J Gastroenterol. 1997 Mar;92(3):454-6.
10
Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study.奥沙拉嗪（双醋苯氧乙柳氮）治疗溃疡性结肠炎患者的疗效与耐受性——一项现场研究的结果
Hepatogastroenterology. 2006 May-Jun;53(69):317-21.
引用本文的文献
1
Comparison of the effects of olsalazine and decitabine on the expression of CDH1 and uPA genes and cytotoxicity in MDA-MB-231 breast cancer cells.奥沙拉嗪与地西他滨对MDA-MB-231乳腺癌细胞中CDH1和uPA基因表达及细胞毒性影响的比较
Res Pharm Sci. 2021 May 12;16(3):278-285. doi: 10.4103/1735-5362.314826. eCollection 2021 Jun.
2
Recent Bio-Advances in Metal-Organic Frameworks.金属有机框架的最新生物进展。
Molecules. 2020 Mar 12;25(6):1291. doi: 10.3390/molecules25061291.
3
Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?炎症性肠病治疗的临床应答和缓解时间：临床医生应该期待什么，应该告诉患者什么？
World J Gastroenterol. 2017 Sep 21;23(35):6385-6402. doi: 10.3748/wjg.v23.i35.6385.
4
Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.溃疡性结肠炎诱导和维持治疗随机试验中的安慰剂反应及缓解率
Cochrane Database Syst Rev. 2017 Sep 8;9(9):CD011572. doi: 10.1002/14651858.CD011572.pub2.
5
Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.改善溃疡性结肠炎中氨基水杨酸盐的给药方式：对患者预后的影响。
Drugs. 2008;68(8):1089-103. doi: 10.2165/00003495-200868080-00006.
6
Meta-analysis of the placebo response in ulcerative colitis.溃疡性结肠炎中安慰剂反应的荟萃分析。
Dig Dis Sci. 2008 Apr;53(4):875-91. doi: 10.1007/s10620-007-9954-6. Epub 2007 Oct 13.
7
Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.奥沙拉嗪在维持静止期克罗恩结肠炎和回结肠炎症缓解方面并不优于安慰剂：一项双盲、平行、随机、多中心研究。
Gut. 2001 Oct;49(4):552-6. doi: 10.1136/gut.49.4.552.
8
Olsalazine in maintenance of clinical remission in patients with ulcerative colitis.
Dig Dis Sci. 1993 Oct;38(10):1837-42. doi: 10.1007/BF01296107.
9
Biliary excretion of olsalazine sodium in humans.
Eur J Drug Metab Pharmacokinet. 1987 Jan-Mar;12(1):17-24. doi: 10.1007/BF03189857.
10
Influence of olsalazine on gastrointestinal transit in ulcerative colitis.奥沙拉嗪对溃疡性结肠炎患者胃肠转运的影响。
Gut. 1987 Nov;28(11):1474-7. doi: 10.1136/gut.28.11.1474.
本文引用的文献
1
CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.柳氮磺胺吡啶治疗溃疡性结肠炎的对照试验
Gut. 1964 Oct;5(5):437-42. doi: 10.1136/gut.5.5.437.
2
Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis.溃疡性结肠炎中皮质类固醇与柳氮磺胺吡啶疗法的比较。
Br Med J. 1962 Dec 29;2(5321):1708-11. doi: 10.1136/bmj.2.5321.1708.
3
Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.柳氮磺胺吡啶和水杨酸偶氮磺胺嘧啶治疗溃疡性结肠炎
Lancet. 1962 May 26;1(7239):1094-6. doi: 10.1016/s0140-6736(62)92080-9.
4
Biopsy studies in ulcerative colitis.溃疡性结肠炎的活检研究。
Br Med J. 1956 Jun 9;1(4979):1315-8. doi: 10.1136/bmj.1.4979.1315.
5
Cortisone in ulcerative colitis; final report on a therapeutic trial.可的松治疗溃疡性结肠炎；一项治疗试验的最终报告
Br Med J. 1955 Oct 29;2(4947):1041-8. doi: 10.1136/bmj.2.4947.1041.
6
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.偶氮双水杨酸二钠在健康志愿者体内的分布与代谢，偶氮双水杨酸二钠是一种潜在的溃疡性结肠炎治疗药物。
Gut. 1982 Dec;23(12):1081-7. doi: 10.1136/gut.23.12.1081.
7
The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis.局部应用N-乙酰-5-氨基水杨酸对溃疡性结肠炎的影响。
Scand J Gastroenterol. 1980;15(6):715-9. doi: 10.3109/00365528009181520.
8
Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas.用4-氨基水杨酸灌肠剂局部治疗远端溃疡性结肠炎。
Digestion. 1984;29(4):231-4. doi: 10.1159/000199038.
9
Reversible male infertility due to sulphasalazine: studies in man and rat.柳氮磺胺吡啶所致的可逆性男性不育：人体和大鼠研究
Gut. 1984 Oct;25(10):1078-84. doi: 10.1136/gut.25.10.1078.
10
Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.通过对健康志愿者和溃疡性结肠炎患者进行体内透析测定结肠偶氮水杨酸代谢情况。
Gastroenterology. 1984 Jun;86(6):1496-500.
Zotero 插件